COMPASS Pathways
We connect science and compassion to reimagine mental health care.
- Headquarters
- London, England
- Employees
- 51–200
- Founded
- 2016
- Business Model
- B2B
- Website
- compasspathways.com
- Total Funding
- $604.0M
- Last Round
- $200.0M Venture RoundFeb 2026
About
COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is developing COMP360 psilocybin therapy, currently in Phase 3 clinical trials for treatment-resistant depression, as well as studies for PTSD and anorexia nervosa. Listed on Nasdaq as CMPS, COMPASS holds FDA Breakthrough Therapy designation for its lead candidate.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account